FindTrial
Sign In

The effect of semaglutide on liver function in NAFLD patietns with DM

The effect of semaglutide on liver function in NAFLD patietns with DM - The effect of semaglutide on liver function in NAFLD patietns with DM

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000046309
Enrollment
50
Registered
2022-12-31
Start date
2022-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD

Interventions

oral semaglutide 24 weeks

Sponsors

Kyoto Prefectural University of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: NAFLD Type 2 diabetes mellitus ALT>31 IU/L

Exclusion criteria

Exclusion criteria: Liver cirrhosis Patients deemed inappropriate by the physician

Design outcomes

Primary

MeasureTime frame
Change in ALT, MRI-PDFF, MR elastography between 24 weeks oral semaglutide therapy—

Countries

Japan

Contacts

Public ContactYuya Seko

Kyoto Prefectural University of Medicine Molecular Gastroenterology and Hepatology

yuyaseko@koto.kpu-m.ac.jp0752515519

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026